Market research
ACW.AU Actinogen Medical Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 229M
- P/E ratio
- Not available
- Analyst target
- 0.08
- Dividend yield
- Not available
- Beta
- 0.89
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000ACW3
- Market cap
- 229M
- P/E ratio
- Not available
- Analyst target
- 0.08
- Dividend yield
- Not available
- Beta
- 0.89
About
About Actinogen Medical Limited
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ACW.AU discussion.
5 years, 6 months ago
Actinogen Medical Limited is currently in a long term uptrend where the price is trading 163.5% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Actinogen Medical Limited's total revenue sank by 71.9% to $16K since the same quarter in the previous year.
Its net income has increased by 41.7% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 115.3% to $533K since the same quarter in the previous year.
Based on the above factors, Actinogen Medical Limited gets an overall score of 4/5.